Medication info
Dapagliflozin/Metformin Extended-release Tablet 10/1000 mg

Dapagliflozin/Metformin Extended-release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped, bilaterally convex extended-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300154 · Approved 2023.01.06 · Insurance code 647805630

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacological treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because changes may cause alterations in glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to decline in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulties in blood sugar control
  • type 2 diabetes
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used to effectively improve blood sugar control in adult patients with type 2 diabetes when combined with dietary and exercise therapies. It is particularly helpful for patients with type 2 diabetes who are not adequately controlled and have cardiovascular disease or risk factors. However, detailed information related to the occurrence of cardiovascular events in these patients should be referred to in professional information. Therefore, this medication provides positive assistance in blood sugar management and cardiovascular health maintenance in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacological treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be titrated gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the dose of metformin the patient was taking, or the nearest therapeutically appropriate dose. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because changes may cause alterations in glycemic control, any change in treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted through the kidneys, and renal function is more likely to decline in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medication helps control blood sugar levels. However, it should not be used in patients with impaired kidney function, dehydration, severe infections, or acute heart diseases. Pregnant or breastfeeding women should also not take this medication. Regular kidney function tests are necessary while taking this medication, and any decrease in body fluid or symptoms of hypotension should be discussed with a physician. There is a risk of hypoglycemia when taken with insulin or sulfonylurea, so dosage adjustments may be necessary. This medication may lead to genital infections or urinary tract infections, and immediate treatment should be sought for any signs of infection. During treatment, vitamin B12 levels may decrease, so regular monitoring is advisable. Excessive alcohol consumption may increase the risk of side effects, so it should be avoided. When undergoing surgery or radiologic contrast examinations, it is necessary to suspend the use of this medication for a period of time and perform kidney function tests before resuming use. Dizziness or symptoms of hypotension may occur, so caution is needed while driving or operating machinery. This medication should be kept out of reach of children and stored in its original container for safety.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • pulmonary malignant neoplasm
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • sialadenopathy
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is essential to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Yellow, oval-shaped, bilaterally convex extended-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.